Use and cardiovascular safety of transdermal and other granisetron preparations in cancer management

Abstract

5-HT₃ antagonists have been available as oral and intravenous preparations for decades. The availability more recently of transdermal granisetron and the anticipated availability of a subcutaneous granisetron preparation have provided helpful alternatives to patients, and these preparations have been shown to have less potential to prolong QT than other drugs in the class.

Keywords:

• chemotherapy-induced nausea
• vomiting
• granisetron
• QT prolongation

Disclosure

Both authors provided consultative support to AP Pharma, Inc, and to ProStrakan, Inc, that is unrelated to this report and its contents. The authors have no other conflicts of interest to disclose.